Efficacy and Safety of Evolocumab (AMG 145), a Fully Human Monoclonal Antibody to PCSK9, in Hyperlipidemic Patients on Various Background Lipid Therapies: Pooled Analysis of 1359 Patients in Four Phase 2 Trials

Study Questions:

What is the effect of a monoclonal antibody to proprotein convertase subtilizin/kexin type 9 (PCSK9 inhibitor) on low-density lipoprotein cholesterol (LDL-C) and other lipoproteins including lipoprotein (a) [Lp(a)], triglycerides, high-density lipoprotein cholesterol (HDL-C), and apolipoproteins (apo B and apo A-1), and adverse events (AEs)?